PATENT CLAIM ANALYSIS

Application Number: 15932251
Application Type: Utility
Filing Date: 2018-02
Publication Date: 2018-08
Patent Classification: ["424", "136100"]

Abstract:
Provided herein multispecific (e.g., bispecific) binding molecules comprising a first binding domain that binds an extracellular portion of dystroglycan and a second binding domain that binds laminin-2. Further provided herein are methods for making such binding molecules and uses of such binding molecules for treating and/or preventing alpha-dystroglycanopathies.

Claim (Index 3):
The multispecific binding molecule of  claim 2 , wherein the binding protein comprises four polypeptide chains, wherein a first polypeptide chain comprises a structure represented by the formula:\n V L2 -L 1 -V L1 -L 2 -C L \u2003\u2003[I] and a second polypeptide chain comprises a structure represented by the formula:\n V H1 -L 3 -V H2 -L 4 -C H1 -hinge-C H2 -C H3 \u2003\u2003[II] \n and a third polypeptide chain comprises a structure represented by the formula:\n V H3 -C H1 -hinge-C H2 -C H3 \u2003\u2003[III] \n and a fourth polypeptide chain comprises a structure represented by the formula:\n V L3 -C L \u2003\u2003[IV] \n wherein:\n V L1  is a first immunoglobulin light chain variable domain; \n V L2  is a second immunoglobulin light chain variable domain; \n V L3  is a third immunoglobulin light chain variable domain; \n V H1  is a first immunoglobulin heavy chain variable domain; \n V H2  is a second immunoglobulin heavy chain variable domain; \n V H3  is a third immunoglobulin heavy chain variable domain; \n C L  is an immunoglobulin light chain constant domain; \n C H1  is an immunoglobulin C H1  heavy chain constant domain; \n C H2  is an immunoglobulin C H2  heavy chain constant domain; \n C H3  is an immunoglobulin C H3  heavy chain constant domain; \n hinge is an immunoglobulin hinge region connecting the C H1  and C H2  domains; and \n L 1 , L 2 , L 3  and L 4  are amino acid linkers; \n wherein the polypeptide of formula I and the polypeptide of formula II form a cross-over light chain-heavy chain pair; and \n wherein V H1  and V L1  form an antigen binding site, wherein V H2  and V L2  form an antigen binding site, and wherein V H3  and V L3  form an antigen binding site for a total of three antigen binding sites, and wherein the three antigen binding sites comprise at least one antigen binding site that binds the extracellular portion of dystroglycan and at least one antigen binding site that binds laminin-2.

Metadata:
- Claim Count in Document: 40.0
- Percentile: 88.0
- Lexical Diversity: 1.43243
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: True
- Related Applications: ['14400642', '14075755', '14539845', '14358520', '15315371']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7790424954479906
- 35 USC 102 Novelty (BERT): 0.5626967253966585
- Combined Prediction Score: 0.7574079184428575
- Mean Citation Score: 462.67613
- Max Citation Score: 468.49353
- Similarity Product: 306.20568520032407

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test